Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ATB200 + AT2221 versus alglucosidase alfa in adults with late-onset Pompe disease
NL-OMON48527Phase 3Completed
- Sponsor
- Amicus Therapeutics
- Start
- Nov 2019
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Pompe disease comparing ATB200 + AT2221 with alglucosidase alfa + placebo (2 arms). Primary endpoint: Change from baseline to Week 52 in 6-minute walk distance. Started Nov 2019; status: completed.
02
Drugs
cipaglucosidase alfamiglustatalglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NL-OMON48527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48527.